Oxolamine (hydrochloride)

Oxolamine hydrochloride (SKF-9976 hydrochloride) is an orally active antitussive. Oxolamine hydrochloride can inhibit CYP2B1/2. Oxolamine hydrochloride has anti-inflammatory effects on the respiratory organs of guinea pigs. Oxolamine hydrochloride increases the AUC of Warfarin (HY-B0687) and prolongs its terminal half-life. Oxolamine hydrochloride can be used in respiratory disease research[1][2][3][4].

Product Specifications

CAS Number

[1219-20-1]

UNSPSC

12352005

Target

Cytochrome P450

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/oxolamine-hydrochloride.html

Smiles

CCN(CC)CCC1=NC(C2=CC=CC=C2)=NO1.Cl

Molecular Formula

C14H20ClN3O

Molecular Weight

281.78

References & Citations

[1]Kirilmaz L, et, al. Sustained-release dosage form of oxolamine citrate: preparation and release kinetics. J Microencapsul. Apr-Jun 1992;9 (2) :167-72.|[2]GIUDICI G, et, al. [On the anti-inflammatory action of oxolamine citrate]. Minerva Med. 1961 Oct 31;52:3752-5.|[3]Zhu X, et al. Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. Biopharm Drug Dispos. 2007 Apr;28 (3) :125-33.|[4]Dahlgren S, et al. The effect of oxolamine citrate on experimentally produced inflammation in the respiratory organs. Acta Pharmacol Toxicol (Copenh) . 1966;24 (2) :286-96.